Vir Biotechnology, Inc. — Director's Dealing 2019

Oct 10, 2019

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Vir Biotechnology, Inc. (VIR)
CIK: 0001706431
Period of Report: 2019-10-10

Reporting Person: Bill & Melinda Gates Foundation (N/A)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A-1 convertible preferred stock	$		Common Stock (2222222)		Direct
Series B convertible preferred stock	$		Common Stock (555555)		Direct

Footnotes

F1: All shares of Series A-1 convertible preferred stock, par value $0.0001 per share and Series B convertible preferred stock, par value $0.0001 per share, have no expiration date and will automatically convert into the Issuer's common stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering.